Wondered

Big Pharma often shelves good drugs. Not because the science failed but because priorities shifted, executives left, or a molecule didn't fit this quarter's strategy. A 28 years old biotech investor at QVT Financial noticed this pattern. In 2014, he founded Roivant Sciences, a company built entirely around exploiting that inefficiency. The name said it all: ROI-vant. Return on Investment. In this...

How does a failed HIV pill transform into a $10 billion immunology biotech empire, only to see its stock crash on the exact day it releases best-in-class clinical data? In this deep-dive documentary episode, we unpack the wild, 1,800% surging ride of Abivax (NASDAQ: ABVX), and explore the incredible origin story of Obefazimod, a first-in-class small molecule that was abandoned as an antiviral but...

What does a failed 1990s medical imaging company have to do with the modern vaping epidemic? Everything. In this episode, we trace the incredible 35-year corporate evolution of Achieve Life Sciences (ACHV). We uncover how two biotech veterans orchestrated a $2 million arbitrage play, took over a public shell via a reverse merger, and positioned a 50-year-old Eastern European smoking pill to comple...

How did Revolution Medicines conquer the "undruggable" KRAS protein? This episode deconstructs the rise of Revolution Medicines (RVMD), a biotech company that paired contrarian science with elite financial engineering to shatter a 40-year oncology stalemate. Time | Topic 02:33 | Why was the KRAS protein considered undruggable for 40 years? 08:18 | How did Revolution Medicines pivot from anti-funga...